PT2575878T - Vacinas compreendendo colesterol e cpg como moléculas únicas adjuvante-portador - Google Patents

Vacinas compreendendo colesterol e cpg como moléculas únicas adjuvante-portador

Info

Publication number
PT2575878T
PT2575878T PT11727536T PT11727536T PT2575878T PT 2575878 T PT2575878 T PT 2575878T PT 11727536 T PT11727536 T PT 11727536T PT 11727536 T PT11727536 T PT 11727536T PT 2575878 T PT2575878 T PT 2575878T
Authority
PT
Portugal
Prior art keywords
cpg
vaccines
cholesterol
carrier molecules
sole adjuvant
Prior art date
Application number
PT11727536T
Other languages
English (en)
Inventor
Lynn Davis Heather
Dhammika Weeratna Risini
Joseph Dominowski Paul
Original Assignee
Zoetis Belgium S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44626939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2575878(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Belgium S A filed Critical Zoetis Belgium S A
Publication of PT2575878T publication Critical patent/PT2575878T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PT11727536T 2010-05-28 2011-05-27 Vacinas compreendendo colesterol e cpg como moléculas únicas adjuvante-portador PT2575878T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34924410P 2010-05-28 2010-05-28

Publications (1)

Publication Number Publication Date
PT2575878T true PT2575878T (pt) 2018-10-03

Family

ID=44626939

Family Applications (1)

Application Number Title Priority Date Filing Date
PT11727536T PT2575878T (pt) 2010-05-28 2011-05-27 Vacinas compreendendo colesterol e cpg como moléculas únicas adjuvante-portador

Country Status (22)

Country Link
US (1) US10456463B2 (pt)
EP (1) EP2575878B1 (pt)
JP (3) JP2011251963A (pt)
KR (1) KR101528021B1 (pt)
CN (1) CN103025351B (pt)
AU (2) AU2011259718B2 (pt)
BR (1) BR112012030337B1 (pt)
CA (1) CA2800158C (pt)
CL (1) CL2012003299A1 (pt)
DK (1) DK2575878T3 (pt)
ES (1) ES2683316T3 (pt)
HR (1) HRP20181039T1 (pt)
HU (1) HUE038894T2 (pt)
LT (1) LT2575878T (pt)
MX (1) MX347471B (pt)
NZ (1) NZ603527A (pt)
PL (1) PL2575878T3 (pt)
PT (1) PT2575878T (pt)
RS (1) RS57428B1 (pt)
SI (1) SI2575878T1 (pt)
WO (1) WO2011148356A1 (pt)
ZA (1) ZA201208837B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
PE20110998A1 (es) 2008-12-09 2012-02-10 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
RU2627447C2 (ru) * 2013-05-14 2017-08-08 ЗОИТИС СЕРВИСЕЗ ЭлЭлСи Новые вакцинные композиции, содержащие иммуностимулирующие олигонуклеотиды
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
EP3046580A2 (en) * 2013-09-19 2016-07-27 Zoetis Services LLC Oil-based adjuvants
WO2015057777A1 (en) 2013-10-17 2015-04-23 Zoetis Llc Methods and compositions for treatment of s. equi infection
CA2932878C (en) * 2013-11-26 2020-11-03 Zoetis Services Llc Compositions for induction of immune response
EP3508198A1 (en) 2014-06-04 2019-07-10 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
PT3244920T (pt) * 2015-01-16 2023-07-28 Zoetis Services Llc Vacina contra a febre aftosa
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
RU2736642C2 (ru) * 2015-07-20 2020-11-19 Зоэтис Сервисиз Ллс Липосомальные адъювантные композиции
KR102116528B1 (ko) 2015-09-09 2020-05-28 칭화 유니버시티 고-효율 백신 아쥬반트로서 메발로네이트 경로 억제제
CN107149671B (zh) * 2016-03-03 2021-02-05 郭文江 一种药物组合物及其应用
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
JP7458977B2 (ja) * 2017-12-15 2024-04-01 エランコ アニマル ヘルス ゲー・エム・ベー・ハー 免疫刺激性組成物
EP3996741A1 (en) * 2019-07-12 2022-05-18 Research Development Foundation Ehrlichia vaccines and immunogenic compositions
IT202100014747A1 (it) * 2021-06-07 2022-12-07 Consiglio Nazionale Ricerche Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore
CN115645417A (zh) * 2022-10-17 2023-01-31 武汉轻工大学 鹅去氧胆酸在制备治疗或预防猪病毒性腹泻的药物或饲料添加剂中的应用
CN118059219B (zh) * 2024-04-19 2024-06-25 西南交通大学 一种肥胖相关乳腺癌的个性化核酸疫苗及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
DE3280400D1 (de) 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
EP1167377B2 (en) * 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO2000009159A1 (en) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP1220684B2 (en) 1999-09-27 2010-07-14 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
CN1301572A (zh) * 1999-10-28 2001-07-04 上海生物制品研究所 用于疫苗的佐剂组合物
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
RU2322258C2 (ru) * 2001-11-07 2008-04-20 Цитос Байотекнолоджи Аг Антигенные матрицы для лечения заболевания костей
JP2005526497A (ja) * 2002-02-04 2005-09-08 ビオミラ，インコーポレーテッド 免疫刺激性、共有結合性脂質化オリゴヌクレオチド
CN100471486C (zh) * 2002-08-12 2009-03-25 戴纳伐克斯技术股份有限公司 免疫调节组合物,其制备方法和使用方法
EP1626737A2 (en) * 2003-05-07 2006-02-22 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
CA2535527A1 (en) * 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic hiv compositions and related methods
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
DE202005022108U1 (de) * 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
US20050266015A1 (en) * 2004-03-12 2005-12-01 Hybridon, Inc. Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
JP2008506683A (ja) * 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
WO2006056142A1 (fr) * 2004-11-29 2006-06-01 Changchun Huapu Biotechnology Co., Ltd. Desoxynucleotides cpg a brin unique a utiliser comme adjuvant
EP1849780A1 (en) * 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
CN101460620B (zh) * 2006-05-31 2012-02-15 东丽株式会社 免疫刺激寡核苷酸及其药物用途
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
KR20100010509A (ko) * 2007-05-17 2010-02-01 콜레이 파마시티컬 그룹, 인코포레이티드 면역자극 효과를 갖는 ａ 클래스 올리고뉴클레오타이드
WO2009120247A2 (en) * 2007-12-27 2009-10-01 The Ohio State University Research Foundation Lipid nanoparticle compositions and methods of making and using the same
DK2310046T3 (da) 2008-06-27 2016-04-25 Zoetis Services Llc Hidtil ukendte adjuvanssammensætninger

Also Published As

Publication number Publication date
CA2800158A1 (en) 2011-12-01
BR112012030337B1 (pt) 2021-04-27
JP6133482B2 (ja) 2017-05-24
ES2683316T3 (es) 2018-09-26
RS57428B1 (sr) 2018-09-28
EP2575878A1 (en) 2013-04-10
HUE038894T2 (hu) 2018-12-28
PL2575878T3 (pl) 2018-12-31
JP2011251963A (ja) 2011-12-15
AU2011259718A1 (en) 2012-12-06
CN103025351B (zh) 2016-08-24
EP2575878B1 (en) 2018-06-13
AU2016203611A1 (en) 2016-06-16
JP6034285B2 (ja) 2016-11-30
US10456463B2 (en) 2019-10-29
JP2017048187A (ja) 2017-03-09
AU2011259718B2 (en) 2016-03-03
BR112012030337A2 (pt) 2017-01-24
JP2013532140A (ja) 2013-08-15
KR20130069668A (ko) 2013-06-26
AU2016203611B2 (en) 2017-06-15
SI2575878T1 (sl) 2018-12-31
US20130084306A1 (en) 2013-04-04
NZ603527A (en) 2014-10-31
CL2012003299A1 (es) 2013-03-08
LT2575878T (lt) 2018-11-12
DK2575878T3 (en) 2018-08-13
HRP20181039T1 (hr) 2018-08-24
CA2800158C (en) 2020-07-21
MX347471B (es) 2017-04-24
CN103025351A (zh) 2013-04-03
KR101528021B1 (ko) 2015-06-10
ZA201208837B (en) 2013-08-28
WO2011148356A1 (en) 2011-12-01
MX2012013731A (es) 2013-12-16

Similar Documents

Publication Publication Date Title
ZA201208837B (en) Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
ZA201307844B (en) Influenza nucleic acid molecules and vaccines made therefrom
IL223206A0 (en) Vaccine formulations
GB201010557D0 (en) RNA molecules and uses thereof
GB201005005D0 (en) New vaccine
EP2563426A4 (en) APPLICATION WITH HIGH SCAM FOR MEDICAL THERAPY
HK1173856A1 (en) Wall-shaped high-frequency assembly hf
EP2529227A4 (en) IMMUNOGENIC PREPARATIONS BASED ON CYTOMEGALOVIRUS
EP2796150A4 (en) NOVEL OLIGONUCLEOTIDE CONJUGATES AND USE THEREOF
EP2855769A4 (en) PAPER-MOUCHOIR COMPRISING MACROALGUES
HK1213017A1 (zh) 天然存在的 寡聚核苷酸組合物及其治療應用
GB201003293D0 (en) Cancer vaccine
GB201014965D0 (en) Vaccine
GB201013006D0 (en) Vaccine
EP2609539A4 (en) VIRTUAL HOT CONNECTION TECHNIQUES
GB201006324D0 (en) Vaccine
ZA201302154B (en) Vaccine
GB201012283D0 (en) Vaccine
GB201007588D0 (en) Vaccine
GB201007589D0 (en) Vaccine
GB201009277D0 (en) Novel vaccine
GB201008795D0 (en) Vaccines
GB201008793D0 (en) vaccines
GB201008788D0 (en) Vaccines
GB201008786D0 (en) Vaccines